ntoifuisa.blogspot.com
Remicade generated sales of $2.8 billion last year for of Horsham, Pa. Schering-Plough, of Kenilworth, posted revenue of more than $2 billion from Remicade sales last year. Simponi was just OK’f by the Food and Drug Administration last In itsarbitration request, Johnsohn & Johnson (NYSE:JNJ), of New N.J., is seeking a ruling that the proposer merger of (NYSE:MRK) and Schering-Plough (NYSE:SGP) constitutesa a change of control that woul permit the termination of the agreements. Mercm and Schering-Plough structured theirt deal as a reverse merger to avoidr triggeringthe change-of-control provision.
In the filing earlier this month with the Securitiesx andExchange Commission, Merck and Schering-Plougy said they will “vigorouslyh contest” any Centocor effort to end the distributioh pact.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment